fbpx

Helix Biopharma Corp

HBP.CA

$0.68

Closing

▼-5.00%

1D

▼-9.52%

YTD

HBP

BBG001S66SP8

Exchange

Sector

Market cap

$33.09M

Volume

4,835

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$33.09M

Analysts' Rating

-

Price Target (Mean)

0

Total Analysts

0

P/E

Operating Margin

0%

Beta

-0.79

Revenue Growth

0%

52 week high

$0.96

52 week low

$0.36

Div. Yield

%

EPS Growth

0

Company Profile

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.